These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 25055035)

  • 1. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars: Hope and concern.
    Emmanouilides CE; Karampola MI; Beredima M
    J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of biosimilars in the treatment of rheumatic diseases.
    Dörner T; Strand V; Castañeda-Hernández G; Ferraccioli G; Isaacs JD; Kvien TK; Martin-Mola E; Mittendorf T; Smolen JS; Burmester GR
    Ann Rheum Dis; 2013 Mar; 72(3):322-8. PubMed ID: 23253920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
    Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
    Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: clinical interpretation and implications for drug development.
    Mysler E
    Curr Rheumatol Rep; 2015 Feb; 17(2):8. PubMed ID: 25618574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders.
    Mirjalili SZ; Sabourian R; Sadeghalvad M; Rezaei N
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108305. PubMed ID: 34741996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for biosimilars in rheumatology in Africa.
    Abu-Zaid MH; Adebajo A; El Miedany Y
    Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.